Evidence map›Paper›PMID 38292643›Full record

ArticleWorld journal of clinical cases2024

Changes in macrophage infiltration and podocyte injury in lupus nephritis patients with repeated renal biopsy: Report of three cases.

Shi-Yuan Liu, Hao Chen, Li-Jia He, Chun-Kai Huang, Pu Wang, Zhang-Ru Rui, Jue Wu, Yang Yuan, Yue Zhang, Wen-Ju Wang and 1 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in World journal of clinical cases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Shi-Yuan LiuCentral Laboratory, Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Yan'an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan Province, China.
Hao ChenDepartment of Nephropathy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan Province, China.
Li-Jia HeCentral Laboratory, Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Yan'an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan Province, China.
Chun-Kai HuangCentral Laboratory, Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Yan'an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan Province, China.
Pu WangCentral Laboratory, Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Yan'an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan Province, China.
Zhang-Ru RuiDepartment of Nephropathy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan Province, China.
Jue WuDepartment of Nephropathy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan Province, China.
Yang YuanDepartment of Nephropathy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan Province, China.
Yue ZhangDepartment of Nephropathy, Yan'an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan Province, China.
Wen-Ju WangCentral Laboratory, Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Yan'an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan Province, China.
Xiao-Dan WangCentral Laboratory, Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Yan'an Hospital Affiliated to Kunming Medical University, Kunming 650051, Yunnan Province, China. wxdky001@163.com.
Kunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn this study, we retrospectively analysed macrophage infiltration and podocyte injury in three patients with diffuse proliferative lupus nephritis (LN) who underwent repeated renal biopsy. CASE SUMMARY: Clinical data of three diffuse proliferative LN patients with different pathological characteristics (case 1 was LN IV-G (A), case 2 was LN IV-G (A) + V, and case 3 was LN IV-G (A) + thrombotic microangiopathy) were reviewed. All patients underwent repeated renal biopsies 6 mo later, and renal biopsy specimens were studied. Macrophage infiltration was assessed by CD68 expression detected by immunohistochemical staining, and an immunofluorescence assay was used to detect podocin expression to assess podocyte damage. After treatment, Case 1 changed to LN III-(A), Case 2 remained as type V LN lesions, and Case 3, which changed to LN IV-S (A), had the worst prognosis. We observed reduced macrophage infiltration after therapy. However, two of the patients with active lesions after treatment still showed macrophage infiltration in the renal interstitium. Before treatment, the three patients showed discontinuous expression of podocin. Notably, the integrity of podocin was restored after treatment in Case 1.

conclusionIt may be possible to reverse podocyte damage and decrease the infiltrating macrophages in LN patients through effective treatment.

Indexed as

Case reportLupus nephritisMacrophagePodocyteRepeat renal biopsyThrombotic microangiopathy

Identifiers

PMID38292643
PMCPMC10824197
OpenAlexW4390488145

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.